Coherus Acquires Bevacizumab Rights From Innovent

Deal Also Includes Option To Sell Innovent’s Rituximab Biosimilar

 
• By David Wallace
Coherus
Coherus has acquired rights to an Avastin biosimilar from Innovent • Source: Shutterstock

More from Deals

More from Business